NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Grady D, Chaput L, Kristof M. Results of Systematic Review of Research on Diagnosis and Treatment of Coronary Heart Disease in Women. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 May. (Evidence Reports/Technology Assessments, No. 80.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Results of Systematic Review of Research on Diagnosis and Treatment of Coronary Heart Disease in Women

Results of Systematic Review of Research on Diagnosis and Treatment of Coronary Heart Disease in Women.

Show details

Appendix E: Cost-effectiveness Analyses and Decision Analyses Articles (N = 21)

  1. Brown AD, Garber AM. Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics 1998;14(1):27–48.
  2. Castillo PA, Palmer CS, Halpern MT, Hatziandreu EJ, Gersh BJ. Cost-effectiveness of thrombolytic therapy for acute myocardial infarction. Ann Pharmacother 1997;31(5):596–603.
  3. Cleland JG, Walker A. Is medical treatment for angina the most cost-effective option? Eur Heart J 1997;18(Suppl B):B35–42.
  4. Davie AP. ACE inhibitors after myocardial infarction. Clinical and economic considerations. Pharmacoeconomics 2000;17(3):237–43.
  5. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999;130(9):719–28.
  6. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Part 2. Ann Intern Med 1996;124(5):518–31.
  7. Goldman L, Coxson P, Hunink MG, Goldman PA, Tosteson AN, Mittleman M, et al. The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. J Am Coll Cardiol 1999;34(3):768–76.
  8. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 2001;19(1):41–55.
  9. Hunink MG, Kuntz KM, Fleischmann KE, Brady TJ. Noninvasive imaging for the diagnosis of coronary artery disease: focusing the development of new diagnostic technology. Ann Intern Med 1999;131(9):673–80.
  10. Kellett J, Clarke J. Comparison of “accelerated” tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction. Med Decis Making 1995;15(4):297–310.
  11. Kuntz KM, Tsevat J, Weinstein MC, Goldman L. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. JAMA 1999;282(23):2246–51.
  12. Marine JE, Freedberg KA, Davidoff R. Cost-effectiveness of stress-echocardiography. Cardiol Clin 1999;17(3):583–95, x.
  13. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332(21):1418–24.
  14. McGregor M, Brophy JM. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty. Can J Cardiol 1999;15(2):201–7.
  15. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG. Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994;14(2):108–17.
  16. Montagne O, Vedel I, Durand-Zaleski I. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. Clin Ther 1999;21(11):2027–35.
  17. Moulds RF. Measurement of cost-effectiveness of drug therapy: a review of the treatment of hypertension. Med J Aust 1990;153(Suppl):S4–6.
  18. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132(10):769–79.
  19. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 2001;286(8):936–43.
  20. van der Weijden T, Knottnerus JA, Ament AJ, Stoffers HE, Grol RP. Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. J Epidemiol Community Health 1998;52(9):586–94.
  21. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990;113(11):852–71.


  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...